According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “
DOVA has been the subject of a number of other research reports. BidaskClub downgraded Dova Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 17th. JPMorgan Chase & Co. raised their price objective on Dova Pharmaceuticals from $13.00 to $15.00 and gave the company an “underweight” rating in a report on Friday, July 12th. HC Wainwright raised their price objective on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Evercore ISI raised Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price objective on the stock in a report on Monday, July 1st. Finally, Wedbush assumed coverage on Dova Pharmaceuticals in a report on Wednesday, May 22nd. They set an “outperform” rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Dova Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $24.57.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.03). The business had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. As a group, analysts expect that Dova Pharmaceuticals will post -2.43 earnings per share for the current fiscal year.
In other news, major shareholder Life Sciences Maste Perceptive acquired 427,209 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The shares were bought at an average cost of $13.35 per share, with a total value of $5,703,240.15. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO David Zaccardelli sold 10,450 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $15.94, for a total value of $166,573.00. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 610,916 shares of company stock worth $8,689,169 and have sold 27,807 shares worth $422,464. Company insiders own 60.30% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC raised its holdings in shares of Dova Pharmaceuticals by 13.7% during the 2nd quarter. Perceptive Advisors LLC now owns 3,553,060 shares of the company’s stock valued at $50,098,000 after buying an additional 427,209 shares in the last quarter. Doyle Wealth Management purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $49,000. Jane Street Group LLC purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $146,000. Morgan Stanley increased its stake in Dova Pharmaceuticals by 102.2% in the 2nd quarter. Morgan Stanley now owns 325,998 shares of the company’s stock worth $4,596,000 after purchasing an additional 164,761 shares during the period. Finally, Paloma Partners Management Co purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $214,000. 32.18% of the stock is currently owned by institutional investors.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
See Also: What is a trade deficit?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.